Patents by Inventor Baltazar Becerril-Lujan

Baltazar Becerril-Lujan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240092879
    Abstract: The present invention relates to a new composition of human recombinant antibody fragments in both single chain or Fab format, which is capable of completely neutralizing the venom of the scorpion Centruroides sculpturatus Ewing (C. sculpturatus. In particular the new composition comprises the scFv fragment 10FG2 (SEQ. ID. No: 1), which has broad cross-reactivity against various Mexican scorpion venom toxins, and the scFv fragment LR (SEQ. ID. No: 2), with more limited cross-reactivity. Alternatively, the new composition comprises the Fab 10FG2 fragment (SEQ. ID. No: 3 and SEQ.ID. No:4) and the Fab LR fragment (SEQ. ID. No: 5 and SEQ.ID. No 6). The two antibody fragments recognize independent epitopes, present in the two main toxins of the scorpion C. sculpturatus, so that they do not interfere with each other during their binding to the same, on the contrary the antibody fragments of the present invention complement the neutralizing activity.
    Type: Application
    Filed: October 3, 2022
    Publication date: March 21, 2024
    Applicant: UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO
    Inventors: Lidia RIAÑO UMBARILA, José Alberto ROMERO MORENO, Lourival Domingos POSSANI POSTAY, Baltazar BECERRIL LUJÁN
  • Patent number: 7381802
    Abstract: The present invention is directed to recombinant human antibodies specific for Cn2 toxin from C. noxius scorpion venom. The antibodies are able to recognize the toxin and preferably neutralize it as well as the whole venom of C. noxius scorpion. This invention is also directed to a human non-immune phage display library. One clone that specifically binds the Cn2 toxin was affinity matured by directed evolution. Three cycles of maturation were performed and several scFv clones were isolated which specifically recognize toxin Cn2 with increased Kd of 446 fold. All variants were monomeric and only variants 6009F, 6105F and 6103E showed to be capable of neutralizing toxin Cn2 and the whole venom. Variant 6009F recognizes a different epitope than that of BCF2, a murine monoclonal antibody raised against scorpion toxin Cn2 which is also capable of neutralizing both Cn2 toxin and the whole venom when tested in mice, as well as that of commercially available polyclonal antibody fragments antivenom from horse.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: June 3, 2008
    Assignee: Universidad Nacional Autónoma De México (UNAM)
    Inventors: Lidia Riaño-Umbarila, Baltazar Becerril Lujan, Lourival Domingos Possani Postay
  • Patent number: 7335759
    Abstract: The invention concerns genes and fusion of genes that code for scorpion toxins and the corresponding polypeptides. The invention also concerns the use of the polypeptides as immunogens for the generation of antibodies that can recognize and neutralize components of scorpion venom as well as for vaccines to prevent envenomation from stings of scorpions of the genus Centruroides, and to immunogenic matrices for the purification of specific immunoglobulins.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: February 26, 2008
    Assignee: Universidad Nacional Autónoma de Méxica (UNAM)
    Inventors: Miguel Corona Villegas, Ma Consuelo Garcia Rodríguez, Georgina Gurrola Briones, Norma Adriana Valdez Cruz, Baltazar Becerril Luján, Lourival Domingos Possani Postay
  • Publication number: 20070071750
    Abstract: The present invention is directed to recombinant human antibodies specific for Cn2 toxin from C. noxius scorpion venom. The antibodies are able to recognize the toxin and preferably neutralize it as well as the whole venom of C. noxius scorpion. This invention is also directed to a human non-immune phage display library. One clone that specifically binds the Cn2 toxin was affinity matured by directed evolution. Three cycles of maturation were performed and several scFv clones were isolated which specifically recognize toxin Cn2 with increased Kd of 446 fold. All variants were monomeric and only variants 6009F, 6105F and 6103E showed to be capable of neutralizing toxin Cn2 and the whole venom. Variant 6009F recognizes a different epitope than that of BCF2, a murine monoclonal antibody raised against scorpion toxin Cn2 which is also capable of neutralizing both Cn2 toxin and the whole venom when tested in mice, as well as that of commercially available polyclonal antibody fragments antivenom from horse.
    Type: Application
    Filed: April 17, 2006
    Publication date: March 29, 2007
    Inventors: Lidia Riano-Umbarila, Baltazar Becerril Lujan, Lourival Possani Postay
  • Publication number: 20050065331
    Abstract: The invention concerns genes and fusion of genes that code for scorpion toxins and the corresponding polypeptides. The invention also concerns the use of the polypeptides as immunogens for the generation of antibodies that can recognize and neutralize components of scorpion venom as well as for vaccines to prevent envenomation from stings of scorpions of the genus Centruroides, and to immunogenic matrices for the purification of specific immunoglobulins.
    Type: Application
    Filed: November 26, 2003
    Publication date: March 24, 2005
    Inventors: Miguel Corona Villegas, Ma Garcia Rodriguez, Georgina Gurrola Briones, Norma Valdez Cruz, Baltazar Becerril Lujan, Lourival Possani Postay
  • Patent number: 6270785
    Abstract: This invention provides insecticidally effective toxins isolated from the venom of the Mexican scorpions of the genus Centruroides and the cDNA encoding one of the toxins.
    Type: Grant
    Filed: April 1, 1998
    Date of Patent: August 7, 2001
    Assignee: Universidad Nacional Autonoma de Mexico
    Inventors: Barbara Selisko, Consuelo Garcia-Rodriguez, Angelina Ramirez-Navarro, Fernando Zamudio-Zuñiga, Baltazar Becerril-Lujan, Lourival D. Possani-Postay